Amneal Pharmaceuticals (AMRX) Non-Current Assets (2017 - 2026)

Amneal Pharmaceuticals' Non-Current Assets history runs 10 years deep, the most recent figure standing at $1.7 billion for Q1 2026.

• On a quarterly basis, Non-Current Assets fell 6.06% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $7.1 billion, a 8.16% decrease from a year earlier, with the FY2025 full-year figure at $1.8 billion, down 7.66% from the prior year.
• Non-Current Assets eased to $1.7 billion in Q1 2026 per AMRX's latest filing, from $1.8 billion in the prior quarter.
• Across five years, Non-Current Assets topped out at $2.5 billion in Q1 2022 and bottomed at $1.7 billion in Q1 2026.
• The 5-year median for Non-Current Assets is $2.1 billion (2024), against an average of $2.1 billion.
• Across the five-year window, Non-Current Assets climbed 4.12% in 2022 and retreated 12.7% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $2.4 billion in 2022, then slipped by 12.26% to $2.1 billion in 2023, then declined by 8.64% to $1.9 billion in 2024, then decreased by 7.66% to $1.8 billion in 2025, then retreated by 1.4% to $1.7 billion in 2026.
• Per Business Quant, the three latest AMRX Non-Current Assets figures stand at $1.7 billion (Q1 2026), $1.8 billion (Q4 2025), and $1.8 billion (Q3 2025).